Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Michael J. Hochman; Gloria F. Gerber; Philip H. Imus; Syed Abbas Ali; Amy E. DeZern

doi:10.1016/j.lrr.2024.100469

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Michael J. Hochman, Gloria F. Gerber, Philip H. Imus, Syed Abbas Ali, Amy E. DeZern

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.

Original language	English (US)
Article number	100469
Journal	Leukemia Research Reports
Volume	22
DOIs	https://doi.org/10.1016/j.lrr.2024.100469
State	Published - Jan 2024

Keywords

Malignancy precursors
Monoclonal gammopathies
Myelodysplastic syndrome
dual hematologic disorders

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.lrr.2024.100469

Cite this

@article{e7e2b1933e5d458581798d405331fa76,

title = "Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series",

abstract = "Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.",

keywords = "Malignancy precursors, Monoclonal gammopathies, Myelodysplastic syndrome, dual hematologic disorders",

author = "Hochman, {Michael J.} and Gerber, {Gloria F.} and Imus, {Philip H.} and Ali, {Syed Abbas} and DeZern, {Amy E.}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = jan,

doi = "10.1016/j.lrr.2024.100469",

language = "English (US)",

volume = "22",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Management of patients with concurrent clonal plasma cell and myeloid disorders

T2 - A single center descriptive case series

AU - Hochman, Michael J.

AU - Gerber, Gloria F.

AU - Imus, Philip H.

AU - Ali, Syed Abbas

AU - DeZern, Amy E.

PY - 2024/1

Y1 - 2024/1

N2 - Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.

AB - Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.

KW - Malignancy precursors

KW - Monoclonal gammopathies

KW - Myelodysplastic syndrome

KW - dual hematologic disorders

UR - http://www.scopus.com/inward/record.url?scp=85198270665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85198270665&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2024.100469

DO - 10.1016/j.lrr.2024.100469

M3 - Article

C2 - 39108700

AN - SCOPUS:85198270665

SN - 2213-0489

VL - 22

JO - Leukemia Research Reports

JF - Leukemia Research Reports

M1 - 100469

ER -

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this